We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYK Stock Declines Despite Steri-Shield Launch to Boost OR Portfolio
Read MoreHide Full Article
Stryker (SYK - Free Report) recently launched the Steri-Shield 8 personal protection system, reinforcing its leadership in medical technologies and personal protective equipment (PPE). Designed in collaboration with healthcare professionals, Steri-Shield 8 prioritizes safety, comfort and enhanced usability for medical teams. This launch aligns with Stryker's broader strategy of continuous innovation and complements its existing product portfolio.
The launch of Steri-Shield 8 exemplifies Stryker’s commitment to innovation and reinforces its leadership in medical safety solutions. By integrating advanced protection features with user-centric design, the system enhances the working conditions of healthcare professionals while complementing the company’s broader portfolio.
Shares of SYK lost 1.3% yesterday following the launch. This was primarily due to broader-market weakness evident from S&P 500 Index’s decline of 1.2%. The company’s shares have, however, improved 6.6% so far this year compared with the industry’s growth of 2.2%. The S&P 500 Index has declined 0.9% in the same period.
Image Source: Zacks Investment Research
Key Features and Benefits of SYK’s Steri-Shield
Steri-Shield 8 integrates advanced features aimed at improving user experience and protection. The system includes a customizable helmet with three points of contact for a secure fit and an accommodating ponytail path for long-haired users. Enhancing visibility, the helmet features a brighter light and a 22% wider field of vision than previous versions.
Additionally, its cooling system strategically targets the front and back of users' necks, ensuring comfort during extended procedures. The inclusion of three toga styles with AAMI Level 4 (2012) protection in all critical zones provides the highest available fluid and microbial barrier, addressing the safety needs of healthcare professionals.
Complementing Stryker’s Existing Portfolio and Recent Launches
The introduction of Steri-Shield 8 strengthens Stryker’s existing MedSurg and Neurotechnology segment, particularly its Instruments and Endoscopy businesses. These divisions have demonstrated strong performance, with organic sales growth exceeding 10% in fourth-quarter 2024. Notably, the launch complements Stryker’s robust offering in surgical environments, aligning with its investments in OR infrastructure, 1788 video platform and smoke evacuation systems.
Furthermore, Steri-Shield 8 aligns with other recent innovations, including the Pangia plating system and the LIFEPAK 35 defibrillator, both of which have driven strong market interest. With Stryker’s continued focus on safety, efficiency and integration across its product lines, this PPE solution supports its commitment to enhancing surgical environments and clinician safety.
Stryker’s Strong Q4 Performance
SYK’s fourth-quarter 2024 earnings highlight its strong market presence and strategic expansion. The company reported revenues of $6.44 billion, reflecting a 10.7% year-over-year increase, with an adjusted EPS of $4.01, exceeding market expectations. Organic sales growth of 10.2% underscores SYK’s ability to sustain high growth across multiple segments, particularly in Instruments, Endoscopy and Trauma & Extremities.
The company’s ongoing portfolio optimization, including the recent decision to divest its Spinal Implants business, allows it to focus on high-growth areas such as interventional spine and enabling technologies. Stryker’s entry into peripheral vascular treatments through its acquisition of Inari Medical further demonstrates its commitment to expanding into high-potential medical markets.
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each.
Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Boston Scientific
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Cardinal Health
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SYK Stock Declines Despite Steri-Shield Launch to Boost OR Portfolio
Stryker (SYK - Free Report) recently launched the Steri-Shield 8 personal protection system, reinforcing its leadership in medical technologies and personal protective equipment (PPE). Designed in collaboration with healthcare professionals, Steri-Shield 8 prioritizes safety, comfort and enhanced usability for medical teams. This launch aligns with Stryker's broader strategy of continuous innovation and complements its existing product portfolio.
The launch of Steri-Shield 8 exemplifies Stryker’s commitment to innovation and reinforces its leadership in medical safety solutions. By integrating advanced protection features with user-centric design, the system enhances the working conditions of healthcare professionals while complementing the company’s broader portfolio.
Shares of SYK lost 1.3% yesterday following the launch. This was primarily due to broader-market weakness evident from S&P 500 Index’s decline of 1.2%. The company’s shares have, however, improved 6.6% so far this year compared with the industry’s growth of 2.2%. The S&P 500 Index has declined 0.9% in the same period.
Image Source: Zacks Investment Research
Key Features and Benefits of SYK’s Steri-Shield
Steri-Shield 8 integrates advanced features aimed at improving user experience and protection. The system includes a customizable helmet with three points of contact for a secure fit and an accommodating ponytail path for long-haired users. Enhancing visibility, the helmet features a brighter light and a 22% wider field of vision than previous versions.
Additionally, its cooling system strategically targets the front and back of users' necks, ensuring comfort during extended procedures. The inclusion of three toga styles with AAMI Level 4 (2012) protection in all critical zones provides the highest available fluid and microbial barrier, addressing the safety needs of healthcare professionals.
Complementing Stryker’s Existing Portfolio and Recent Launches
The introduction of Steri-Shield 8 strengthens Stryker’s existing MedSurg and Neurotechnology segment, particularly its Instruments and Endoscopy businesses. These divisions have demonstrated strong performance, with organic sales growth exceeding 10% in fourth-quarter 2024. Notably, the launch complements Stryker’s robust offering in surgical environments, aligning with its investments in OR infrastructure, 1788 video platform and smoke evacuation systems.
Furthermore, Steri-Shield 8 aligns with other recent innovations, including the Pangia plating system and the LIFEPAK 35 defibrillator, both of which have driven strong market interest. With Stryker’s continued focus on safety, efficiency and integration across its product lines, this PPE solution supports its commitment to enhancing surgical environments and clinician safety.
Stryker’s Strong Q4 Performance
SYK’s fourth-quarter 2024 earnings highlight its strong market presence and strategic expansion. The company reported revenues of $6.44 billion, reflecting a 10.7% year-over-year increase, with an adjusted EPS of $4.01, exceeding market expectations. Organic sales growth of 10.2% underscores SYK’s ability to sustain high growth across multiple segments, particularly in Instruments, Endoscopy and Trauma & Extremities.
The company’s ongoing portfolio optimization, including the recent decision to divest its Spinal Implants business, allows it to focus on high-growth areas such as interventional spine and enabling technologies. Stryker’s entry into peripheral vascular treatments through its acquisition of Inari Medical further demonstrates its commitment to expanding into high-potential medical markets.
Stryker Corporation Stock Price
Stryker Corporation price | Stryker Corporation Quote
SYK’s Zacks Rank and Other Key Picks
Stryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each.
Masimo’s shares have rallied 30.1% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo
Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Boston Scientific
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Cardinal Health
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.